Suppr超能文献

为尤因肉瘤构建EWS-FLI1驱动的转基因小鼠模型面临的挑战。

Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.

作者信息

Ramachandran Balaji, Rajkumar Thangarajan, Gopisetty Gopal

机构信息

Department of Molecular Oncology, Cancer Institute (W.I.A) No. 38, Sardar Patel Road, Adyar, Chennai 600036, India.

出版信息

Am J Transl Res. 2021 Nov 15;13(11):12181-12194. eCollection 2021.

Abstract

EWS-FLI1 is a master regulator of Ewing sarcoma (ES) oncogenesis. Although EWS-FLI1 represents a clear therapeutic target, targeted therapeutic inhibitors are lacking. Scientific literature has indicated accumulating information pertaining to EWS-FLI1 translocation, pathogenesis, function, oncogenic partnerships, and potential clinical relevance. However, attempts to develop EWS-FLI1-driven human-like ES mouse models or in systems ended up with limited success. Establishing such models as preclinical screening tools may accelerate the development of EWS-FLI1 targeted therapeutic inhibitors. This review summarizes the current scenario, which focuses on the limitations, challenges, and possible reasons for past failures in model development and also plausible alternatives.

摘要

EWS-FLI1是尤因肉瘤(ES)肿瘤发生的主要调节因子。尽管EWS-FLI1是一个明确的治疗靶点,但缺乏靶向治疗抑制剂。科学文献表明,有关EWS-FLI1易位、发病机制、功能、致癌伙伴关系及潜在临床相关性的信息不断积累。然而,尝试开发由EWS-FLI1驱动的类人ES小鼠模型或体外系统,最终取得的成功有限。建立此类模型作为临床前筛选工具可能会加速EWS-FLI1靶向治疗抑制剂的开发。本综述总结了当前的情况,重点关注模型开发中过去失败的局限性、挑战和可能原因,以及合理的替代方案。

相似文献

1
Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.
Am J Transl Res. 2021 Nov 15;13(11):12181-12194. eCollection 2021.
3
Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.
Oncotarget. 2017 May 23;8(21):34141-34163. doi: 10.18632/oncotarget.9388.
5
EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Cancer Sci. 2018 Sep;109(9):2907-2918. doi: 10.1111/cas.13710. Epub 2018 Jul 18.
6
Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
J Clin Invest. 2014 Dec;124(12):5275-90. doi: 10.1172/JCI72124. Epub 2014 Nov 17.
7
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Clin Cancer Res. 2015 Sep 15;21(18):4184-93. doi: 10.1158/1078-0432.CCR-14-2112. Epub 2015 Mar 16.
8
A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197. Epub 2011 Jun 6.
9
Slit2 signaling stimulates Ewing sarcoma growth.
Genes Cancer. 2022 Dec 14;13:88-99. doi: 10.18632/genesandcancer.227. eCollection 2022.
10
Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Expert Opin Ther Targets. 2014 Nov;18(11):1315-28. doi: 10.1517/14728222.2014.947963. Epub 2014 Aug 27.

引用本文的文献

2
Druggable upregulated proteins in EWS-FLI-driven Ewing sarcoma as emerging new therapeutic targets.
Am J Transl Res. 2025 Mar 15;17(3):1580-1603. doi: 10.62347/YMEU1808. eCollection 2025.
4
Refined culture conditions with increased physiological relevance uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids.
Cell Rep Methods. 2025 Feb 24;5(2):100966. doi: 10.1016/j.crmeth.2025.100966. Epub 2025 Feb 7.
5
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma.
Mol Ther Oncol. 2024 Sep 26;32(4):200886. doi: 10.1016/j.omton.2024.200886. eCollection 2024 Dec 19.
6
Preclinical models for the study of pediatric solid tumors: focus on bone sarcomas.
Front Oncol. 2024 Jul 18;14:1388484. doi: 10.3389/fonc.2024.1388484. eCollection 2024.
9
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.
Int J Biol Sci. 2023 Jun 26;19(11):3360-3382. doi: 10.7150/ijbs.83026. eCollection 2023.

本文引用的文献

1
Expression of the EWSR1-FLI1 fusion oncogene in pancreas cells drives pancreatic atrophy and lipomatosis.
Pancreatology. 2020 Dec;20(8):1673-1681. doi: 10.1016/j.pan.2020.10.033. Epub 2020 Oct 10.
2
The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer.
J Bone Oncol. 2020 May 31;23:100300. doi: 10.1016/j.jbo.2020.100300. eCollection 2020 Aug.
3
Wnt/β-catenin-activated Ewing sarcoma cells promote the angiogenic switch.
JCI Insight. 2020 Jul 9;5(13):135188. doi: 10.1172/jci.insight.135188.
5
Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells.
BMC Cancer. 2020 Jan 2;20(1):3. doi: 10.1186/s12885-019-6465-8.
6
The Fusion Oncogene FUS-CHOP Drives Sarcomagenesis of High-Grade Spindle Cell Sarcomas in Mice.
Sarcoma. 2019 Jul 25;2019:1340261. doi: 10.1155/2019/1340261. eCollection 2019.
7
CD151 confers metastatic potential to clear cell sarcoma of the soft tissue in animal model.
Oncol Lett. 2019 Jun;17(6):4811-4818. doi: 10.3892/ol.2019.10164. Epub 2019 Mar 19.
9
Insight into the Etiology of Undifferentiated Soft Tissue Sarcomas from a Novel Mouse Model.
Mol Cancer Res. 2019 May;17(5):1024-1035. doi: 10.1158/1541-7786.MCR-18-0117. Epub 2019 Jan 25.
10
FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer.
PLoS Comput Biol. 2018 Jul 24;14(7):e1006266. doi: 10.1371/journal.pcbi.1006266. eCollection 2018 Jul.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验